Decreased Cerebrospinal Fluid Abeta(42) Correlates with Brain Atrophy in Cognitively Normal Elderly

Overview

Journal Ann Neurol

Specialty Neurology

Date 2009 Mar 5

PMID 19260027

Citations 180

Authors

Anne M Fagan

Denise Head

Aarti R Shah

Daniel Marcus

Mark Mintun

John C Morris

David M Holtzman

Affiliations

Soon will be listed here.

Abstract

Objective: For therapies for Alzheimer's disease (AD) to have the greatest impact, it will likely be necessary to treat individuals in the "preclinical" (presymptomatic) stage. Fluid and neuroimaging measures are being explored as possible biomarkers of AD pathology that could aid in identifying individuals in this stage to target them for clinical trials and to direct and monitor therapy. The objective of this study was to determine whether cerebrospinal fluid (CSF) biomarkers for AD suggest the presence of brain damage in the preclinical stage of AD.

Methods: We investigated the relation between structural neuroimaging measures (whole-brain volume) and levels of CSF amyloid-beta (Abeta)(40), Abeta(42), tau, and phosphorylated tau(181) (ptau(181)), and plasma Abeta(40) and Abeta(42) in well-characterized research subjects with very mild and mild dementia of the Alzheimer type (n = 29) and age-matched, cognitively normal control subjects (n = 69).

Results: Levels of CSF tau and ptau(181), but not Abeta(42), correlated inversely with whole-brain volume in very mild and mild dementia of the Alzheimer type, whereas levels of CSF Abeta(42), but not tau or ptau(181), were positively correlated with whole-brain volume in nondemented control subjects.

Interpretation: Reduction in CSF Abeta(42), likely reflecting Abeta aggregation in the brain, is associated with brain atrophy in the preclinical phase of AD. This suggests that there is toxicity associated with Abeta aggregation before the onset of clinically detectable disease. Increases in CSF tau (and ptau(181)) are later events that correlate with further structural damage and occur with clinical onset and progression.

Citing Articles

Hippocampal Subfield Volume in Relation to Cerebrospinal Fluid Amyloid-ß in Early Alzheimer's Disease: Diagnostic Utility of 7T MRI.

Adeyemi O, Gowland P, Bowtell R, Mougin O, Hosseini A Eur J Neurol. 2025; 32(2):e70076.

PMID: 39921301 PMC: 11806197. DOI: 10.1111/ene.70076.

Elevated locus coeruleus metabolism provides resilience against cognitive decline in preclinical Alzheimer's disease.

Koops E, Dutta J, Hanseeuw B, Becker J, Van Egroo M, Prokopiou P Alzheimers Dement. 2024; 21(1):e14385.

PMID: 39588792 PMC: 11772725. DOI: 10.1002/alz.14385.

Effect of Treatment of the Cholinergic Precursor Choline Alphoscerate in Mild Cognitive Dysfunction: A Randomized Controlled Trial.

Carotenuto A, Andreone V, Amenta F, Traini E Medicina (Kaunas). 2024; 60(6).

PMID: 38929542 PMC: 11205363. DOI: 10.3390/medicina60060925.

CSF biomarkers of immune activation and Alzheimer's disease for predicting cognitive impairment risk in the elderly.

Shue F, White L, Hendrix R, Ulrich J, Henson R, Knight W Sci Adv. 2024; 10(14):eadk3674.

PMID: 38569027 PMC: 10990276. DOI: 10.1126/sciadv.adk3674.

Correlational analyses of biomarkers that are harmonized through a bridging study due to measurement errors.

Xiong C, Schindler S, Henson R, Wolk D, Shaw L, Agboola F Stat Methods Med Res. 2023; 33(2):185-202.

PMID: 37994004 PMC: 10939855. DOI: 10.1177/09622802231215810.

References

Silbert L, Quinn J, Moore M, Corbridge E, Ball M, Murdoch G . Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology. 2003; 61(4):487-92. DOI: 10.1212/01.wnl.0000079053.77227.14. View

Fagan A, Mintun M, Mach R, Lee S, Dence C, Shah A . Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2005; 59(3):512-9. DOI: 10.1002/ana.20730. View

Zhang Y, Brady M, Smith S . Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging. 2001; 20(1):45-57. DOI: 10.1109/42.906424. View

Kanai M, Matsubara E, ISOE K, Urakami K, Nakashima K, Arai H . Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol. 1998; 44(1):17-26. DOI: 10.1002/ana.410440108. View

Andreasen N, Vanmechelen E, Van de Voorde A, Davidsson P, Hesse C, Tarvonen S . Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry. 1998; 64(3):298-305. PMC: 2170016. DOI: 10.1136/jnnp.64.3.298. View

Jack Jr C, Dickson D, Parisi J, Xu Y, Cha R, OBrien P . Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology. 2002; 58(5):750-7. PMC: 2745935. DOI: 10.1212/wnl.58.5.750. View

Schoonenboom N, van der Flier W, Blankenstein M, Bouwman F, Van Kamp G, Barkhof F . CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Neurobiol Aging. 2007; 29(5):669-75. DOI: 10.1016/j.neurobiolaging.2006.11.018. View

Cirrito J, May P, ODell M, Taylor J, Parsadanian M, Cramer J . In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003; 23(26):8844-53. PMC: 6740389. View

Buckner R, Head D, Parker J, Fotenos A, Marcus D, Morris J . A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage. 2004; 23(2):724-38. DOI: 10.1016/j.neuroimage.2004.06.018. View

10.

Fischl B, Salat D, Busa E, Albert M, Dieterich M, Haselgrove C . Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002; 33(3):341-55. DOI: 10.1016/s0896-6273(02)00569-x. View

11.

Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel S . CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2006; 129(Pt 11):3035-41. DOI: 10.1093/brain/awl269. View

12.

de Leon M, DeSanti S, Zinkowski R, Mehta P, Pratico D, Segal S . Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging. 2005; 27(3):394-401. DOI: 10.1016/j.neurobiolaging.2005.07.003. View

13.

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L . Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006; 5(3):228-34. DOI: 10.1016/S1474-4422(06)70355-6. View

14.

Price J, Morris J . Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999; 45(3):358-68. DOI: 10.1002/1531-8249(199903)45:3<358::aid-ana12>3.0.co;2-x. View

15.

Storandt M, Grant E, Miller J, Morris J . Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology. 2006; 67(3):467-73. DOI: 10.1212/01.wnl.0000228231.26111.6e. View

16.

Archer H, Edison P, Brooks D, Barnes J, Frost C, Yeatman T . Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol. 2006; 60(1):145-7. DOI: 10.1002/ana.20889. View

17.

Hampel H, Burger K, Pruessner J, Zinkowski R, DeBernardis J, Kerkman D . Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol. 2005; 62(5):770-3. DOI: 10.1001/archneur.62.5.770. View

18.

Kantarci K, Jack Jr C . Quantitative magnetic resonance techniques as surrogate markers of Alzheimer's disease. NeuroRx. 2005; 1(2):196-205. PMC: 534925. DOI: 10.1602/neurorx.1.2.196. View

19.

Li G, Sokal I, Quinn J, Leverenz J, Brodey M, Schellenberg G . CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007; 69(7):631-9. DOI: 10.1212/01.wnl.0000267428.62582.aa. View

20.

Galasko D, Chang L, Motter R, Clark C, Kaye J, Knopman D . High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998; 55(7):937-45. DOI: 10.1001/archneur.55.7.937. View